{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:04:26Z","timestamp":1790640266542,"version":"4.1.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":398,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>Fibroblast growth factor receptor (FGFR) tyrosine kinases, which are expressed on the cell membrane, are involved in a wide range of biological functions such as cell proliferation, survival, migration, and differentiation. The identification of FGFR fusions and other alterations in a wide range of solid tumors, including cholangiocarcinoma and bladder cancer, has resulted in the development of several selective FGFR inhibitors for use in these indications, for example, infigratinib, erdafitinib, derazantinib, pemigatinib, and futibatinib. In addition to the typical adverse events associated with tyrosine kinases, the FGFR inhibitors appear to give rise to a number of adverse events affecting the skin. Here we describe these skin events, which include the more common nail adverse events (e.g., onycholysis), palmar\u2013plantar erythrodysesthesia syndrome, and stomatitis, as well as less common reactions such as calciphylaxis. This review aims to provide oncologists with an understanding of these dermatologic events and proposes guidelines for the management of treatment-emergent dermatologic adverse events. Awareness of possible adverse events associated with specific drugs should allow physicians to educate patients as to what to expect and implement effective management plans at the earliest possible opportunity, thereby preventing premature discontinuation while maintaining patient quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>Identification of fibroblast growth factor receptor (FGFR) aberrations in cholangiocarcinoma and bladder cancer led to development of selective FGFR inhibitors for these indications, based on clinical benefit and safety profiles. The most frequent adverse events (AEs) include those affecting skin, hair, and nails, a unique class effect of these agents. These are usually mild to moderate in severity. This work reviewed skin AEs reported with FGFR inhibitors and provides management guidelines for physicians, aiming to increase awareness of skin events and provide effective treatment strategies. Early intervention and effective management may improve treatment adherence, optimize outcomes, and improve quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1002\/onco.13552","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T06:00:16Z","timestamp":1601964016000},"page":"e316-e326","source":"Crossref","is-referenced-by-count":62,"title":["Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines"],"prefix":"10.1093","volume":"26","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Anadkat","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[{"name":"Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Guindon","sequence":"additional","affiliation":[{"name":"QED Therapeutics, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"2021122511550638700_onco13552-bib-0001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2021122511550638700_onco13552-bib-0002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fnins.2011.00133","article-title":"FGFs: Neurodevelopment's Jack-of-all-trades - How do they do it?","volume":"5","author":"Hebert","year":"2011","journal-title":"Front Neurosci"},{"key":"2021122511550638700_onco13552-bib-0003","doi-asserted-by":"crossref","first-page":"17218","DOI":"10.1074\/jbc.RA118.003036","article-title":"Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation","volume":"293","author":"Regeenes","year":"2018","journal-title":"J Biol Chem"},{"key":"2021122511550638700_onco13552-bib-0004","doi-asserted-by":"crossref","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"key":"2021122511550638700_onco13552-bib-0005","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"2021122511550638700_onco13552-bib-0006","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-14-0284","article-title":"FGFR1\/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer","volume":"20","author":"Wang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122511550638700_onco13552-bib-0007","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"2021122511550638700_onco13552-bib-0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"2021122511550638700_onco13552-bib-0009","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122511550638700_onco13552-bib-0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"Kirstein","year":"2016","journal-title":"Visc Med"},{"key":"2021122511550638700_onco13552-bib-0011","volume-title":"SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Based on November 2017 SEER data submission, posted to the SEER web site, April 2018. 2018","author":"Noone"},{"issue":"suppl 1","key":"2021122511550638700_onco13552-bib-0012","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"2021122511550638700_onco13552-bib-0013","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2021122511550638700_onco13552-bib-0014","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"The Oncologist"},{"key":"2021122511550638700_onco13552-bib-0015","volume-title":"Key statistics for bile duct cancer","author":"American Cancer Society","year":"2018"},{"key":"2021122511550638700_onco13552-bib-0016","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122511550638700_onco13552-bib-0017","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122511550638700_onco13552-bib-0018","author":"National Comprehensive Cancer Network"},{"issue":"suppl 15","key":"2021122511550638700_onco13552-bib-0019","doi-asserted-by":"crossref","first-page":"4003a","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy","volume":"37","author":"Lamarca","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2021122511550638700_onco13552-bib-0021","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"2021122511550638700_onco13552-bib-0022","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122511550638700_onco13552-bib-0023","author":"American Cancer Society"},{"key":"2021122511550638700_onco13552-bib-0024","author":"National Cancer Institute","year":"2019"},{"key":"2021122511550638700_onco13552-bib-0025","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"2021122511550638700_onco13552-bib-0026","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA Approval Summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"The Oncologist"},{"key":"2021122511550638700_onco13552-bib-0027","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0028","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122511550638700_onco13552-bib-0029","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1083\/jcb.200910126","article-title":"Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis","volume":"188","author":"Yang","year":"2010","journal-title":"J Cell Biol"},{"key":"2021122511550638700_onco13552-bib-0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov"},{"key":"2021122511550638700_onco13552-bib-0031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature12214","article-title":"Wnt activation in nail epithelium couples nail growth to digit regeneration","volume":"499","author":"Takeo","year":"2013","journal-title":"Nature"},{"key":"2021122511550638700_onco13552-bib-0032","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511550638700_onco13552-bib-0033","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamadermatol.2017.0500","article-title":"Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors","volume":"153","author":"Betrian","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"suppl 15","key":"2021122511550638700_onco13552-bib-0034","article-title":"First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)","volume":"36","author":"Siefker-Radtke","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0035","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0036","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2021122511550638700_onco13552-bib-0037","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"2021122511550638700_onco13552-bib-0038","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2018.5071","article-title":"Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia","volume":"155","author":"Freites-Martinez","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2021122511550638700_onco13552-bib-0039","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"2021122511550638700_onco13552-bib-0040","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl 8","key":"2021122511550638700_onco13552-bib-0041","doi-asserted-by":"crossref","first-page":"viii319","DOI":"10.1093\/annonc\/mdy283.109","article-title":"Interim results of FIGHT-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)\/FGF receptor (FGFR) genetic alterations (GA)","volume":"29","author":"Necchi","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2021122511550638700_onco13552-bib-0042","doi-asserted-by":"crossref","first-page":"4117a","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122511550638700_onco13552-bib-0043","doi-asserted-by":"crossref","first-page":"108a","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0044","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"2021122511550638700_onco13552-bib-0045","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"The Oncologist"},{"key":"2021122511550638700_onco13552-bib-0046","first-page":"e61","article-title":"The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"suppl 15","key":"2021122511550638700_onco13552-bib-0047","doi-asserted-by":"crossref","first-page":"16122a","DOI":"10.1200\/jco.2008.26.15_suppl.16122","article-title":"Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL)","volume":"26","author":"Huggins","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0048","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"The Oncologist"},{"issue":"suppl 6","key":"2021122511550638700_onco13552-bib-0049","doi-asserted-by":"crossref","first-page":"489a","DOI":"10.1200\/JCO.2020.38.6_suppl.489","article-title":"FORT-1: Phase II\/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1\/3 mRNA expression","volume":"38","author":"Quinn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122511550638700_onco13552-bib-0050","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaad.2014.12.010","article-title":"Incidence and risk of xerosis with targeted anticancer therapies","volume":"72","author":"Valentine","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2021122511550638700_onco13552-bib-0051","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1741-2358.2003.00064.x","article-title":"Xerostomia: Clinical aspects and treatment","volume":"20","author":"Cassolato","year":"2003","journal-title":"Gerodontology"},{"key":"2021122511550638700_onco13552-bib-0052","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fgene.2018.00542","article-title":"Bones, glands, ears and more: The multiple roles of FGF10 in craniofacial development","volume":"9","author":"Prochazkova","year":"2018","journal-title":"Front Genet"},{"key":"2021122511550638700_onco13552-bib-0053","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamadermatol.2018.4070","article-title":"Metastatic calcinosis cutis associated with a selective FGFR inhibitor","volume":"155","author":"Carr","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2021122511550638700_onco13552-bib-0054","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cup.13319","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor","volume":"45","author":"Arudra","year":"2018","journal-title":"J Cutan Pathol"},{"key":"2021122511550638700_onco13552-bib-0055","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"2021122511550638700_onco13552-bib-0056","doi-asserted-by":"crossref","first-page":"14003","DOI":"10.1038\/boneres.2014.3","article-title":"Role of FGF\/FGFR signaling in skeletal development and homeostasis: Learning from mouse models","volume":"2","author":"Su","year":"2014","journal-title":"Bone Res"},{"key":"2021122511550638700_onco13552-bib-0057","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/cvr\/cvx178","article-title":"Regulation of vascular smooth muscle cell calcification by syndecan-4\/FGF-2\/PKCalpha signalling and cross-talk with TGFbeta","volume":"113","author":"Borland","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2021122511550638700_onco13552-bib-0058","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10637-019-00825-0","article-title":"A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for cancer therapy-associated paronychia","volume":"37","author":"Capriotti","year":"2019","journal-title":"Invest New Drugs"},{"key":"2021122511550638700_onco13552-bib-0059","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00520-010-0837-6","article-title":"A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact","volume":"18","author":"Jensen","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122511550638700_onco13552-bib-0060","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2006.08.065","article-title":"Calciphylaxis: Natural history, risk factor analysis, and outcome","volume":"56","author":"Weenig","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2021122511550638700_onco13552-bib-0061","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.jaad.2011.06.009","article-title":"Calciphylaxis: A systematic review of existing and emerging therapies","volume":"67","author":"Vedvyas","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2021122511550638700_onco13552-bib-0062","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamadermatol.2013.4565","article-title":"Intralesional sodium thiosulfate for the treatment of calciphylaxis","volume":"149","author":"Strazzula","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2021122511550638700_onco13552-bib-0063","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2017.4920","article-title":"Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: A case-control study","volume":"154","author":"Dobry","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2021122511550638700_onco13552-bib-0064"},{"key":"2021122511550638700_onco13552-bib-0065","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"key":"2021122511550638700_onco13552-bib-0066","doi-asserted-by":"crossref","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","volume":"151","author":"Roskoski R Jr","year":"2020","journal-title":"Pharmacol Res"},{"key":"2021122511550638700_onco13552-bib-0067","doi-asserted-by":"crossref","first-page":"e0162594","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation","volume":"11","author":"Hall","year":"2016","journal-title":"PLoS One"},{"key":"2021122511550638700_onco13552-bib-0068","author":"Sootome H, Fujita H, Ito K","journal-title":"Cancer Res"},{"key":"2021122511550638700_onco13552-bib-0069","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"suppl 19","key":"2021122511550638700_onco13552-bib-0070","first-page":"2014","article-title":"Preclinical profile of BAY 1163877 - A selective pan-FGFR inhibitor in phase 1 clinical trial","volume":"74","author":"Heroult","year":"1739","journal-title":"Cancer Res"},{"key":"2021122511550638700_onco13552-bib-0071","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284\/Debio 1347, a novel selective FGFR inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"suppl 4","key":"2021122511550638700_onco13552-bib-0072","doi-asserted-by":"crossref","first-page":"447a","DOI":"10.1200\/JCO.2018.36.4_suppl.447","article-title":"Safety and efficacy of the selective FGFR inhibitor Debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC)","volume":"36","author":"Cleary","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13552","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/2\/e316\/41923658\/oncolo_26_2_e316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/2\/e316\/41923658\/oncolo_26_2_e316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T14:50:59Z","timestamp":1723733459000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/2\/e316\/6445357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":72,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,28]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13552","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,10,28]]}}}